If you’re interested in mycology, you’ve probably been surprised by how vast the world of fungi really is. But some species, like Psilocybe cubensis, steal the spotlight. You’ve probably heard of this strain of psychedelic mushroom before - it’s the gold-cap mushroom, or Golden Teacher.
P. cubensis is one of a small cohort of fungi that form the basis of research into psychedelic mushrooms. Scholars have marked a “sharp increase” in studies on psilocybin in recent years. P. cubensis and synthetic copies are often used for its safety profile and availability. Here’s what you need to know about Psilocybe cubensis, and why it’s so popular among hobbyists and lab coats alike.
Psilocybe cubensis is considered “the” magic mushroom. First identified by mycologist Franklin Summer Earle in 1906 in Cuba but described as ‘Stropharia cubensis’, the species was moved into the genus Psilocybe in 1949 by German-born mycologist Rolf Singer, giving it the binomial name Psilocybe cubensis.
Later, in the 1970s, brothers Dennis and Terrance McKenna would publish the game-changing Psilocybin: Magic Mushroom Grower’s Guide, which popularized casual cultivation and was based on their experiences hunting exotic spores in the Colombian Amazon.
P. cubensis, commonly called “Golden Teacher,” has since been identified and cultivated all over the world. Psilocybe comes from the Greek word for “bare head,” while cubensis describes its original location of discovery in Cuba.
Psilocybe cubensis is usually ingested orally, with effects lasting between two and six hours. The dosing threshold is 0.25 grams, with light dosages ranging from 0.25g to 1g; common dosages range up to 2.5 grams. Anything above 2.5 grams is considered a heavy or “hero” dose.
Psilocybe cubensis earned its “Golden Teacher” moniker from the mycology community due to its properties and appearance - Psilocybe cubensis’ psychoactive effects have been said to elicit a deep and introspective experience. The result? A reputation for sparking inspiration and reflection.
Beyond the hype, Psilocybe cubensis may be more commonly known in some circles as “gold cap,” for its white-gold coloration.
Psilocybe cubensis is among the most commonly used psilocybin-producing mushrooms in scientific research due to its availability. When scholars and scientists conduct trials, they first use Golden Teacher or a chemically identical synthetic alternative.
The hallucinogenic and reality-distorting effects of psilocybin have been well-documented for decades.
Newer research on P. cubensis and other Psilocybes has converged on potential mental health utility, with data showing that organic psilocybin, and synthetic, lab-grown copies alike, may combat depressive symptoms in a similar manner to pharmaceutical drugs.
Most psychedelic mushrooms are generally safe to consume in moderate dosages. That said, there are risks to ingesting any psychoactive substance. Niche cases of acute ingestion causing uncommon adverse effects such as kidney damage have been reported. Meanwhile, some scholars have advocated for better reporting and management of side effects in research protocols.
Synthetic psilocybin derivatives may be leading the clinical charge, especially concerning mental health, but it’s worth noting not all of its mechanistic effects are fully understood. Institutions like Cambridge University have highlighted the applicability of P. cubensis but have also called for more specific research.
Meanwhile, P. cubensis and other psychedelic mushrooms are being dissected for relevance beyond the mental or mystical scope of their effects.
There are still plenty of unknowns about Psilocybe cubensis. But science is finally coming around on the versatile, holistic potential of psychedelic mushrooms - even if, compared to many indigenous cultures and practices, they’re playing catch-up.
Psilocybe cubensis is found worldwide. Widespread proliferation explains its relevance to Indigenous cultures and spiritual practices, but that proliferation itself is due to its biological resilience.
As a coprophilous or ‘dung-loving’ fungus, Psilocybe cubensis thrives on animal droppings, particularly that of common herbivores like cows and horses. It’s partial to humid, tropical and subtropical climates, and has been found in the tropical and subtropical regions of Central and South America, Southeast Asia, and Australia. Crucially, P. cubensis is easy to cultivate at home or in laboratory settings.
Psilocybin is a Schedule I controlled substance in the United States, according to the U.S. Drug Enforcement Agency. It is federally illegal to possess, ingest, sell, or distribute. But on a practical level, things are murkier due to conflicting local laws and growing medical validity for psilocybes like Golden Teacher.
In 2018, the U.S. Food & Drug Administration granted “breakthrough therapy” status to psychedelics, widening its applicability window. And certain states, like Oregon and Colorado, have passed measures expanding therapeutic access to certain psychedelics, enabling a broader scope of research applications. Overseas, the legality of psilocybin varies too, but laws are generally more lax in Central America and Europe.
The variability here stems in part from psilocybin’s complex legal history and in part from its cultural significance. Regardless of Psilocybe cubensis’s positive reputation, standard psychedelic best practices apply:
1. Kryskow, Pam & La Torre, Joseph & Sattler, Katherine & Tsang, Vivian & Williams, Monnica. (2024). “The mushroom was more alive and vibrant”: Patient reports of synthetic versus organic forms of psilocybin. Journal of Psychedelic Studies. 8. 303-312. 10.1556/2054.2024.00379.
2. McLaughlin, Stephen & Kane, Liam & Helbert, Yvonne & Zhang, Lei & Houde, Nathan & McKernan, Kevin. (2021). A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production7-2-21. 10.5281/zenodo.5062843.
3. Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., & Forbes, M. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/nejmoa2206443
4. Austin E, Myron HS, Summerbell RK, Mackenzie C. Acute renal injury cause by confirmed Psilocybe cubensis mushroom ingestion. Med Mycol Case Rep. 2018 Dec 22;23:55-57. doi: 10.1016/j.mmcr.2018.12.007. PMID: 30627509; PMCID: PMC6322052.
5. Bukovsky D, Amaev A, Song J, Kyte S, Carmona-Torres E, Ueno F, Deluca V, Strafella AP, Husain MI, Graff-Guerrero A, Gerretsen P. Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development. Prog Neuropsychopharmacol Biol Psychiatry. 2025 Dec 20;143:111541. doi: 10.1016/j.pnpbp.2025.111541. Epub 2025 Oct 23. PMID: 41138900.
6. Lin MCQ, Lee H, Tsang VWL, et al. Systematic Review on the Mechanisms of Action of Psilocybin in the Treatment of Depression. European Psychiatry. 2023;66(S1):S416-S417. doi:10.1192/j.eurpsy.2023.898
7. Schindler EAD, Gottschalk CH, Pittman BP, D'Souza DC. Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial. Headache. 2025 Dec 29. doi: 10.1111/head.70024. Epub ahead of print. PMID: 41459830.
8. Mandrake, K. (2024). The psilocybin mushroom bible: the definitive guide to growing and using magic mushrooms. Green Candy Press.
9. R.C. Van Court, M.S. Wiseman, K.W. Meyer, D.J. Ballhorn, K.R. Amses, J.C. Slot, B.T.M. Dentinger, R. Garibay-Orijel, J.K. Uehling, Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development, Fungal Biology, Volume 126, Issue 4, 2022, Pages 308-319, ISSN 1878-6146
10. Simonsson O, Goldberg SB, Osika W, Stenfors CUD, Chaturvedi S, Swords CM, Narayanan J, Hendricks PS. Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms. Psychol Med. 2025 Mar 31;55:e99. doi: 10.1017/S0033291725000716. PMID: 40162511; PMCID: PMC12094617.
11. Kopra EI, Ferris JA, Winstock AR, Young AH, Rucker JJ. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. J Psychopharmacol. 2022 Aug;36(8):965-973. doi: 10.1177/02698811221084063. Epub 2022 Apr 7. PMID: 35388724; PMCID: PMC9353971.